Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print          Annual reports

Tuesday 18 May, 2021

AstraZeneca PLC

Director/PDMR Shareholding

RNS Number : 0386Z
AstraZeneca PLC
18 May 2021


18 May 2021 15:30 BST


Transaction by Person Discharging Managerial Responsibilities


AstraZeneca PLC (the Company) announced that on 14 May 2021, Pascal Soriot, Chief Executive Officer, was granted an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.


This award forms part of the AZPSP award granted to Mr Soriot on 5 March 2021. As described in AstraZeneca's 2020 Directors' Remuneration Report, it has been made in accordance with the Directors' Remuneration Policy and amended rules of the AZPSP approved by shareholders at the Company's 2021 Annual General Meeting.



Ordinary Shares granted under the AZPSP

Award price per Ordinary Share

Pascal Soriot




The award is subject to a combination of performance measures focused on scientific, commercial, financial and ESG performance.  Further details of the performance measures attached to the AZPSP award can be found in AstraZeneca's 2020 Directors' Remuneration Report, which is contained within the AstraZeneca Annual Report and Form 20-F Information 2020 (available on the Company's website at


The performance measures will be assessed over a three-year performance period (1 January 2021 to 31 December 2023). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.




Details of the person discharging managerial responsibilities / person closely associated







Pascal Soriot



Reason for the notification







Chief Executive Officer



Initial notification /Amendment



Initial notification



Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor







AstraZeneca PLC









Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted





Description of the financial instrument, type of instrument


Identification code



Ordinary Shares of US$0.25 each in AstraZeneca PLC







Nature of the transaction



Grant of a share award under the AstraZeneca Performance Share Plan



Price(s) and volume(s)













Aggregated information



- Aggregated volume



- Price



Not applicable - single transaction






Date of the transaction



14 May 2021



Place of the transaction



Outside a trading venue


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.


AstraZeneca contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.


Adrian Kemp

Company Secretary

AstraZeneca PLC



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t